Metformin Reverses Development of Pulmonary Hypertension via Aromatase Inhibition

Hypertension

Volumn 68, Issue 2, 2016, Pages 446-454

  Dean, Afshan ^a   Nilsen, Margaret ^a   Loughlin, Lynn ^a   Salt, Ian P ^a   MacLean, Margaret R ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

AMP activated protein kinase; aromatase; estrogen; metformin; pulmonary hypertension

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ACETYL COENZYME A CARBOXYLASE; ANASTROZOLE; AROMATASE; AROMATIC HYDROCARBON RECEPTOR; CYCLINE; CYTOCHROME P450 1B1; ESTRADIOL; ESTROGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; METFORMIN; SEMAXANIB; ANTIDIABETIC AGENT; AROMATASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL PROLIFERATION; ENZYME ACTIVITY; ENZYME INHIBITION; ESTRADIOL BLOOD LEVEL; ESTROGEN METABOLISM; ESTROGEN SYNTHESIS; FEMALE; HEART RIGHT VENTRICLE HYPERTROPHY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PULMONARY ARTERY; PULMONARY ARTERY SMOOTH MUSCLE CELL; PULMONARY HYPERTENSION; RAT; REPORTER GENE; SYSTOLIC BLOOD PRESSURE; ANIMAL; BIOSYNTHESIS; CELL LINE; DRUG EFFECTS; HYPERTENSION, PULMONARY; LUNG; METABOLISM; PATHOLOGY; SMOOTH MUSCLE CELL; VASCULAR REMODELING;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; AROMATASE; AROMATASE INHIBITORS; CELL LINE; CELL PROLIFERATION; ESTROGENS; HUMANS; HYPERTENSION, PULMONARY; HYPOGLYCEMIC AGENTS; LUNG; METFORMIN; MYOCYTES, SMOOTH MUSCLE; PULMONARY ARTERY; RATS; VASCULAR REMODELING;

EID: 84974718889     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.116.07353     Document Type: Article

References (50)

1. McLaughlin VV, Gaine SP, Howard LS, Leuchte HH, Mathier MA, Mehta S, Palazzini M, Park MH, Tapson VF, Sitbon O. Treatment goals of pulmonary hypertension. J Am Coll Cardiol. 2013;62(suppl 25):D73-D81. doi: 10.1016/j.jacc.2013.10.034.
2. Mair KM, Johansen AK, Wright AF, Wallace E, MacLean MR. Pulmonary arterial hypertension: basis of sex differences in incidence and treatment response. Br J Pharmacol. 2014;171:567-579. doi: 10.1111/bph.12281.
3. Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE, Barst RJ, Benza RL, Liou TG, Turner M, Giles S, Feldkircher K, Miller DP, McGoon MD. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010;137:376-387. doi: 10.1378/chest.09-1140.
4. Shapiro S, Traiger GL, Turner M, McGoon MD, Wason P, Barst RJ. Sex differences in the diagnosis, treatment, and outcome of patients with pulmonary arterial hypertension enrolled in the registry to evaluate early and long-term pulmonary arterial hypertension disease management. Chest. 2012;141:363-373. doi: 10.1378/chest.10-3114.
5. Tofovic SP. Estrogens and development of pulmonary hypertension: interaction of estradiol metabolism and pulmonary vascular disease. J Cardiovasc Pharmacol. 2010;56:696-708. doi: 10.1097/ FJC.0b013e3181f9ea8d.
6. Paulin R, Michelakis ED. The estrogen puzzle in pulmonary arterial hypertension. Circulation. 2012;126:1016-1019. doi: 10.1161/ CIRCULATIONAHA.112.126474.
7. Wright AF, Ewart MA, Mair K, Nilsen M, Dempsie Y, Loughlin L, Maclean MR. Oestrogen receptor alpha in pulmonary hypertension. Cardiovasc Res. 2015;106:206-216. doi: 10.1093/cvr/cvv106.
8. Lahm T. Sex differences in pulmonary hypertension: are we cleaning up the mess? Eur Respir J. 2016;47:390-393. doi: 10.1183/13993003. 01999-2015.
9. Rabinovitch M, Gamble WJ, Miettinen OS, Reid L. Age and sex influence on pulmonary hypertension of chronic hypoxia and on recovery. Am J Physiol. 1981;240:H62-H72.
10. Lahm T, Albrecht M, Fisher AJ, Selej M, Patel NG, Brown JA, Justice MJ, Brown MB, Van Demark M, Trulock KM, Dieudonne D, Reddy JG, Presson RG, Petrache I. 17β-Estradiol attenuates hypoxic pulmonary hypertension via estrogen receptor-mediated effects. Am J Respir Crit Care Med. 2012;185:965-980. doi: 10.1164/rccm.201107-1293OC.
11. Parker TA, Ivy DD, Galan HL, Grover TR, Kinsella JP, Abman SH. Estradiol improves pulmonary hemodynamics and vascular remodeling in perinatal pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2000;278:L374-L381.
12. Frump AL, Goss KN, Vayl A, Albrecht M, Fisher A, Tursunova R, Fierst J, Whitson J, Cucci AR, Brown MB, Lahm T. Estradiol improves right ventricular function in rats with severe angioproliferative pulmonary hypertension: effects of endogenous and exogenous sex hormones. Am J Physiol Lung Cell Mol Physiol. 2015;308:L873-L890. doi: 10.1152/ ajplung.00006.2015.
13. White K, Dempsie Y, Nilsen M, Wright AF, Loughlin L, MacLean MR. The serotonin transporter, gender, and 17β oestradiol in the development of pulmonary arterial hypertension. Cardiovasc Res. 2011;90:373-382. doi: 10.1093/cvr/cvq408.
14. Dempsie Y, Nilsen M, White K, Mair KM, Loughlin L, Ambartsumian N, Rabinovitch M, Maclean MR. Development of pulmonary arterial hypertension in mice over-expressing S100A4/Mts1 is specific to females. Respir Res. 2011;12:159. doi: 10.1186/1465-9921-12-159.
15. Dempsie Y, MacRitchie NA, White K, Morecroft I, Wright AF, Nilsen M, Loughlin L, Mair KM, MacLean MR. Dexfenfluramine and the oestrogen-metabolizing enzyme CYP1B1 in the development of pulmonary arterial hypertension. Cardiovasc Res. 2013;99:24-34. doi: 10.1093/cvr/ cvt064.
16. White K, Johansen AK, Nilsen M, Ciuclan L, Wallace E, Paton L, Campbell A, Morecroft I, Loughlin L, McClure JD, Thomas M, Mair KM, MacLean MR. Activity of the estrogen-metabolizing enzyme cytochrome P450 1B1 influences the development of pulmonary arterial hypertension. Circulation. 2012;126:1087-1098. doi: 10.1161/ CIRCULATIONAHA.111.062927.
17. Mair KM, Wright AF, Duggan N, Rowlands DJ, Hussey MJ, Roberts S, Fullerton J, Nilsen M, Loughlin L, Thomas M, MacLean MR. Sexdependent influence of endogenous estrogen in pulmonary hypertension. Am J Respir Crit Care Med. 2014;190:456-467. doi: 10.1164/ rccm.201403-0483OC.
18. Ventetuolo CE, Mitra N, Wan F, Manichaikul A, Barr RG, Johnson C, Bluemke DA, Lima JA, Tandri H, Ouyang P, Kawut SM. Oestradiol metabolism and androgen receptor genotypes are associated with right ventricular function. Eur Respir J. 2016;47:553-563. doi: 10.1183/13993003.01083-2015.
19. Huang S, Chen P, Shui X, He Y, Wang H, Zheng J, Zhang L, Li J, Xue Y, Chen C, Lei W. Baicalin attenuates transforming growth factor-β1-induced human pulmonary artery smooth muscle cell proliferation and phenotypic switch by inhibiting hypoxia inducible factor-1α and aryl hydrocarbon receptor expression. J Pharm Pharmacol. 2014;66:1469-1477. doi: 10.1111/jphp.12273.
20. Goodarzi MO, Bryer-Ash M. Metformin revisited: re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents. Diabetes Obes Metab. 2005;7:654-665. doi: 10.1111/j.1463-1326.2004.00448.x.
21. Rojas LB, Gomes MB. Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr. 2013;5:6. doi: 10.1186/1758-5996-5-6.
22. Miller RA, Chu Q, Xie J, Foretz M, Viollet B, Birnbaum MJ. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature. 2013;494:256-260. doi: 10.1038/nature11808.
23. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol. 2012;13:251-262. doi: 10.1038/nrm3311.
24. Ewart MA, Kennedy S. Diabetic cardiovascular disease-AMP-activated protein kinase (AMPK) as a therapeutic target. Cardiovasc Hematol Agents Med Chem. 2012;10:190-211.
25. Brown KA, Hunger NI, Docanto M, Simpson ER. Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase. Breast Cancer Res Treat. 2010;123:591-596. doi: 10.1007/s10549-010-0834-y.
26. Palomba S, Falbo A, Zullo F, Orio F Jr. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr Rev. 2009;30:1-50. doi: 10.1210/er.2008-0030.
27. Brown KA, McInnes KJ, Hunger NI, Oakhill JS, Steinberg GR, Simpson ER. Subcellular localization of cyclic AMP-responsive element binding protein-regulated transcription coactivator 2 provides a link between obesity and breast cancer in postmenopausal women. Cancer Res. 2009;69:5392-5399. doi: 10.1158/0008-5472.CAN-09-0108.
28. Agard C, Rolli-Derkinderen M, Dumas-de-La-Roque E, Rio M, Sagan C, Savineau JP, Loirand G, Pacaud P. Protective role of the antidiabetic drug metformin against chronic experimental pulmonary hypertension. Br J Pharmacol. 2009;158:1285-1294. doi: 10.1111/j.1476-5381.2009.00445.x.
29. Abe K, Toba M, Alzoubi A, Ito M, Fagan KA, Cool CD, Voelkel NF, McMurtry IF, Oka M. Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. Circulation. 2010;121:2747-2754. doi: 10.1161/CIRCULATIONAHA.109.927681.
30. Gomez-Arroyo JG, Farkas L, Alhussaini AA, Farkas D, Kraskauskas D, Voelkel NF, Bogaard HJ. The monocrotaline model of pulmonary hypertension in perspective. Am J Physiol Lung Cell Mol Physiol. 2012;302:L363-L369. doi: 10.1152/ajplung.00212.2011.
31. Lephart ED, Simpson ER. Assay of aromatase activity. Methods Enzymol. 1991;206:477-483. doi: 10.1016/0076-6879(91)06116-K
32. Hadad SM, Hardie DG, Appleyard V, Thompson AM. Effects of metformin on breast cancer cell proliferation, the AMPK pathway and the cell cycle. Clin Transl Oncol. 2014;16:746-752. doi: 10.1007/s12094-013-1144-8.
33. Sesen J, Dahan P, Scotland SJ, Saland E, Dang V-T, Lemarié A, Tyler BM, Brem H, Toulas C, Moyal E, Sarry JE, Skuli N. Metformin inhibits growth of human glioblastoma cells and enhances therapeutic response. PLoS One. 2015;10:1-24. doi: 10.1371/journal.pone.0123721
34. Roberts KE, Fallon MB, Krowka MJ, et al; Pulmonary Vascular Complications of Liver Disease Study Group. Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am J Respir Crit Care Med. 2009;179:835-842. doi: 10.1164/ rccm.200809-1472OC.
35. Xu JN, Zeng C, Zhou Y, Peng C, Zhou YF, Xue Q. Metformin inhibits StAR expression in human endometriotic stromal cells via AMPKmediated disruption of CREB-CRTC2 complex formation. J Clin Endocrinol Metab. 2014;99:2795-2803. doi: 10.1210/jc.2014-1593.
36. Seeger H, Wallwiener D, Kraemer E, Mueck AO. Estradiol metabolites are potent mitogenic substances for human ovarian cancer cells. Eur J Gynaecol Oncol. 2005;26:383-385.
37. Jiao H, Liu C, Guo W, Peng L, Chen Y, Martin FL. Association of CYP1B1 Polymorphisms with Breast Cancer: A Case-Control Study in the Han Population in Ningxia Hui Autonomous Region, P. R. China. Biomark Insights. 2010;5:21-27.
38. Do MT, Kim HG, Tran TT, Khanal T, Choi JH, Chung YC, Jeong TC, Jeong HG. Metformin suppresses CYP1A1 and CYP1B1 expression in breast cancer cells by down-regulating aryl hydrocarbon receptor expression. Toxicol Appl Pharmacol. 2014;280:138-148. doi: 10.1016/j. taap.2014.07.021.
39. Yang X, Solomon S, Fraser LR, Trombino AF, Liu D, Sonenshein GE, Hestermann EV, Sherr DH. Constitutive regulation of CYP1B1 by the aryl hydrocarbon receptor (AhR) in pre-malignant and malignant mammary tissue. J Cell Biochem. 2008;104:402-417. doi: 10.1002/jcb.21630.
40. Jacob A, Hartz AM, Potin S, Coumoul X, Yousif S, Scherrmann JM, Bauer B, Declèves X. Aryl hydrocarbon receptor-dependent upregulation of Cyp1b1 by TCDD and diesel exhaust particles in rat brain microvessels. Fluids Barriers CNS. 2011;8:23. doi: 10.1186/2045-8118-8-23.
41. Yin XF, Chen J, Mao W, Wang YH, Chen MH. Downregulation of aryl hydrocarbon receptor expression decreases gastric cancer cell growth and invasion. Oncol Rep. 2013;30:364-370. doi: 10.3892/or.2013.2410.
42. Zhang N. The role of endogenous aryl hydrocarbon receptor signaling in cardiovascular physiology. J Cardiovasc Dis Res. 2011;2:91-95. doi: 10.4103/0975-3583.83033.
43. Abdou HS, Bergeron F, Tremblay JJ. A cell-autonomous molecular cascade initiated by AMP-activated protein kinase represses steroidogenesis. Mol Cell Biol. 2014;34:4257-4271. doi: 10.1128/MCB.00734-14.
44. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108:1167-1174. doi: 10.1172/ JCI13505.
45. Lee YK, Park SY, Kim YM, Lee WS, Park OJ. AMP kinase/cyclooxygenase-2 pathway regulates proliferation and apoptosis of cancer cells treated with quercetin. Exp Mol Med. 2009;41:201-207. doi: 10.3858/ emm.2009.41.3.023.
46. Kim J, Kundu M, Viollet B, Guan KL. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol. 2011;13:132-141. doi: 10.1038/ncb2152.
47. Hirsch A, Hahn D, Kempná P, Hofer G, Mullis PE, Nuoffer JM, Flück CE. Role of AMP-activated protein kinase on steroid hormone biosynthesis in adrenal NCI-H295R cells. PLoS One. 2012;7:e30956. doi: 10.1371/ journal.pone.0030956.
48. Lim CT, Kola B, Korbonits M. AMPK as a mediator of hormonal signalling. J Mol Endocrinol. 2010;44:87-97. doi: 10.1677/JME-09-0063.
49. Ibe JC, Zhou Q, Chen T, Tang H, Yuan JX, Raj JU, Zhou G. Adenosine monophosphate-activated protein kinase is required for pulmonary artery smooth muscle cell survival and the development of hypoxic pulmonary hypertension. Am J Respir Cell Mol Biol. 2013;49:609-618. doi: 10.1165/ rcmb.2012-0446OC.
50. Austin ED, Cogan JD, West JD, Hedges LK, Hamid R, Dawson EP, Wheeler LA, Parl FF, Loyd JE, Phillips JA III. Alterations in oestrogen metabolism: implications for higher penetrance of familial pulmonary arterial hypertension in females. Eur Respir J. 2009;34:1093-1099. doi: 10.1183/09031936.00010409.